1
|
Ghaddhab C, Capper CC, Larrivée-Vanier S, Fayad W, Olivier P, Van Vliet G, Auchus RJ, Deladoëy J. Severe aldosterone synthase deficiency in a nine-day old Lebanese boy: the importance of functional studies to establish pathogenicity of seemingly benign variants in CYP11B2. Horm Res Paediatr 2024:000536437. [PMID: 38316111 DOI: 10.1159/000536437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 01/19/2024] [Indexed: 02/07/2024] Open
Abstract
Introduction Aldosterone synthase deficiency is a rare autosomal recessive disease characterized by vomiting, dehydration, salt wasting, life-threatening hyperkalemia in infancy, followed by failure to thrive. It results from pathogenic variants in CYP11B2. Case Presentation A boy, born in Montreal to Lebanese parents who are first cousins, was referred at nine days of life for severe dehydration. A diagnosis of primary adrenal insufficiency was made, and treatment was started with fludrocortisone and hydrocortisone. Exome sequencing revealed a homozygous variant p.(Asn201Asp)(N201D). In silico, this variant was considered benign, but in vitro functional expression studies established it caused the severe aldosterone deficiency. It ended the diagnostic odyssey and allowed to safely stop hydrocortisone replacement. Conclusion If a gene variant co-segregates with a phenotype, in vitro functional studies are required even if in silico studies are negative.
Collapse
|
2
|
Grangeret J, Imbert L, Claudin M, Bros M, Bordonne M, Olivier P, Marie P, Verger A, Boursier Joppin C. La scintigraphie au Lutétium a-t-elle une place dans le suivi des traitements par 177Lu-PSMA ? Une évaluation thérapeutique multitraceurs. Médecine Nucléaire 2023. [DOI: 10.1016/j.mednuc.2023.01.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
3
|
Martin R, Vincent B, Olivier P, Marie-Agnès G, Ulricke S, François L. PO-1265 Title: DLCO decrease in a prospective cohort of VMAT-treated lung cancer patients (NCT03931356). Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03229-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
4
|
Bologna S, Vander Borght T, Briere J, Ribrag V, Damaj GL, Thieblemont C, Feugier P, Peyrade F, Lebras L, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquieres H, Becker S, Olivier P, Fabiani B, Tilly H, Haioun C, Bastie JN. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.5_2879] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S Bologna
- Hématologie Privée Nancéienne 54 Essey lès Nancy France
| | | | - J Briere
- CHU Henri Mondor 94 Créteil France
| | - V Ribrag
- Institut Gustave Roussy 94 Villejuif France
| | | | | | - P Feugier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - F Peyrade
- Centre Antoine Lacassagne 06 Nice France
| | - L Lebras
- Centre Léon Berard 69 Lyon, France
| | - D Coso
- Institut Paoli Calmette 13 Marseille France
| | - D Sibon
- Hôpital Necker-Enfants Malades 75 Paris France
| | | | | | | | - S Becker
- Centre Henri Becquerel 76 Rouen France
| | - P Olivier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - B Fabiani
- Hopital Saint Antoine 75 Paris France
| | - H Tilly
- Centre Henry Becquerel 76 Rouen France
| | - C Haioun
- Hopital Henri Mondor 94 Créteil France
| | | |
Collapse
|
5
|
Diaz Escagedo P, Fiscaletti M, Olivier P, Hudon C, Miranda V, Miron MC, Campeau PM, Alos N. Rickets manifestations in a child with metaphyseal anadysplasia, report of a spontaneously resolving case. BMC Pediatr 2021; 21:248. [PMID: 34022834 PMCID: PMC8140414 DOI: 10.1186/s12887-021-02716-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Accepted: 05/12/2021] [Indexed: 12/04/2022] Open
Abstract
Introduction Rickets is not an unusual diagnosis for pediatricians even currently in developed countries. Children typically present with leg bowing, enlargement of wrists, rachitic rosary (swelling of costochondral junctions) and/or waddling gait. But not every child with growth delay and enlarged metaphyses is diagnosed with rickets. Metaphyseal anadysplasia (MAD) is a disorder of variable severity with metaphyseal flaring and irregularities, without vertebral abnormalities. MAD is characterized by an early onset and a regressive course in late childhood without treatment, despite persistent short stature. Autosomal dominant or recessive variants in the matrix metalloproteinase 13 gene (MMP13) are responsible for these transient metaphyseal changes. Case presentation We report a new pathogenic heterozygous variant in MMP13 (NM_002427.4: c.216G>C, p.Gln72His) in a toddler, initially thought to have rickets, and his father, with MAD phenotypes. Additionally, we review the seven reported MMP13 variants. Conclusion One should keep a wide differential diagnosis in cases of suspected rickets, including skeletal dysplasias which might have a regressive course. Supplementary Information The online version contains supplementary material available at 10.1186/s12887-021-02716-x.
Collapse
Affiliation(s)
- Patricia Diaz Escagedo
- Bone and mineral Clinic, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada
| | - Melissa Fiscaletti
- Bone and mineral Clinic, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada
| | - Patricia Olivier
- Bone and mineral Clinic, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada
| | - Chloé Hudon
- Medical Genetics Service, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada
| | - Valancy Miranda
- Medical Genetics Service, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada
| | - Marie-Claude Miron
- Radiology Department, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada
| | - Philippe M Campeau
- Medical Genetics Service, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada. .,Research Center, Sainte-Justine Hospital Center, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada.
| | - Nathalie Alos
- Bone and mineral Clinic, Sainte-Justine Hospital Center, Department of Pediatrics, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada. .,Research Center, Sainte-Justine Hospital Center, 3175 Chemin de la Côte-Sainte-Catherine, Montreal, QC, Canada.
| |
Collapse
|
6
|
Champagne M, Olivier P, Glavas P, Cantin MA, Rauch F, Alos N, Campeau PM. A de novo frameshift FGFR1 mutation extending the protein in an individual with multiple epiphyseal dysplasia and hypogonadotropic hypogonadism without anosmia. Eur J Med Genet 2020; 63:103784. [DOI: 10.1016/j.ejmg.2019.103784] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 08/12/2019] [Accepted: 10/06/2019] [Indexed: 11/24/2022]
|
7
|
Pouessel D, Mervoyer A, Larrieu-Ciron D, Cabarrou B, Robert M, Frenel J, Olivier P, Mounier M, Cohen-Jonathan Moyal E. OS4.4 Hypofractionated stereotactic radiotherapy and anti-PDL1 Durvalumab combination in recurrent glioblastoma: Results of the phase I part of the phase I/II STERIMGLI trial. Neuro Oncol 2019; 21:iii10-iii11. [PMCID: PMC6795045 DOI: 10.1093/neuonc/noz126.034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2023] Open
Abstract
Abstract
BACKGROUND
Glioblastoma (GBM) remains a lethal disease with inevitable local relapse and no standard treatment. Re-irradiation by hypofractionated stereotactic radiotherapy (hFSRT) is an option of treatment with tolerable safety, but needs improvement in term of efficacy. Radiotherapy (RT) causes immunogenic tumor cell death but also induces PDL1 and PD1 expression on tumors and immune cells, potentially evoking resistance to RT. Pre-clinical studies combining hFSRT with an anti-PD-1 antibody in GBM have shown increased efficacy of the combination. Clinical studies also show encouraging results when checkpoint inhibitors have been combined with high dose RT. We hypothesized that combining the anti PD-L1 Durvalumab (Durva) with hFSRT will be an effective regimen for patients with recurrent GBM. We designed a phase I/II clinical trial studying the combination of hFSRT with Durva for recurrent GBM≤35 mm diameter. Results of the phase I are presented.
MATERIAL AND METHODS
Patients were included from February 2017 to October 2017.
A standard 3 + 3 de-escalation design was used. Patients were treated by hFSRT 24 Gy, 8 Gy/fraction at 80% isodose, every other day, combined with Durva infusion 1500mg first dose (Level 1) or 750 mg (Level -1) delivered on the last hFSRT day followed by 1500 mg Durva infusion every four weeks until relapse. The schema was defined as safe if one patient or less among 6 presents a dose limiting toxicity (DLT). Brain MRI was performed before RT and then every 8 weeks until relapse. Tumor assessment was performed according to RANO criteria.
RESULTS
Among the 6 patients (3 methylated MGMT, 3 unmethylated MGMT; all wild type IDH) included at the level 1, all completed the hFSRT course, only one had a DLT which was an immune related grade 3 vestibular neuritis. At the time of analysis (24/01/19), all the patients had a local tumor progression, 4 were still alive. Local progression free interval (LPFI) ranges from 2.1 to 8.1 months. Interestingly the 2 patients who presented a pseudo-progression had a prolonged LPFI (5.7 and 8.1 months) compared to the other patients. All the patients except these 2 patients had a lymphopenia at inclusion. PDL-1 expression varied from 0 to 70% in the primary tumor.
CONCLUSION
Combining three 8 Gy fractions of hFSRT with 1500 mg Durvalumab on the 3rd fraction hFSRT and every 4 weeks for recurrent GBM is well tolerated justifying exploration of its efficacy in the phase II which is currently in interim analysis
Collapse
Affiliation(s)
- D Pouessel
- Institut Claudius Regaud-IUCT-O, Toulouse, France
| | - A Mervoyer
- Institut de Cancerologie de l’Ouest, Saint Herblain, France
| | | | - B Cabarrou
- Institut Claudius Regaud-IUCT-O, Toulouse, France
| | - M Robert
- Institut de Cancerologie de l’Ouest, Saint Herblain, France
| | - J Frenel
- Institut de Cancerologie de l’Ouest, Saint Herblain, France
| | - P Olivier
- Centre Régional de Pharmacovigilance, Toulouse, France
| | - M Mounier
- Institut Claudius Regaud-IUCT-O, Toulouse, France
| | | |
Collapse
|
8
|
Hampton P, Richardson D, Brown S, Goodhead C, Montague K, Olivier P. Usability testing of MySkinSelfie: a mobile phone application for skin self-monitoring. Clin Exp Dermatol 2019; 45:73-78. [PMID: 31021009 DOI: 10.1111/ced.13995] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2019] [Indexed: 12/01/2022]
Abstract
Teledermatology generally involves doctors taking images of patients; however, patients increasingly want to own or have easy access to their health data. MySkinSelfie ( http://myskinselfie.com) is a mobile phone application (app) designed to improve the quality, consistency and accessibility of patient-held photos, and was developed to give patients the ability to generate and hold their own skin images to help guide their skin care. This study assessed the usability of this app in a cohort of patients attending a National Health Service Dermatology clinic. Patients were asked to use the app but were not given specific tasks to achieve. Of the 102 patients recruited, 32 downloaded the app and registered an account, 21 took at least one photo (median 5, range 1-103) and 19 completed the usability questionnaire. The majority of questionnaire respondents found the app easy to use but were more neutral on whether it really helped them to manage their skin problem. MySkinSelfie has been shown to be easy to use. Self-monitoring of skin problems may be useful for a subset of patients, and this is likely to depend on diagnosis, age and other patient factors.
Collapse
Affiliation(s)
- P Hampton
- Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - D Richardson
- Open Lab, School of Computing Science, Newcastle University, Newcastle upon Tyne, UK
| | - S Brown
- Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - C Goodhead
- Department of Dermatology, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK
| | - K Montague
- Open Lab, School of Computing Science, Newcastle University, Newcastle upon Tyne, UK
| | - P Olivier
- Open Lab, School of Computing Science, Newcastle University, Newcastle upon Tyne, UK
| |
Collapse
|
9
|
Mourey L, Ravaud A, Digue L, Cabarrou B, Gomez-Roca C, Valentin T, Olivier P, Fabre A, Mounier M, Balardy L, Filleron T. VOTRAGE study pazopanib in a population of “frail” elderly patients after geriatric assessment: A phase I study with geriatric criteria. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.107] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Larrieu-Ciron D, Peyraga G, Pouessel D, Mervoyer A, Cabarrou B, Attal J, Robert M, Olivier P, Mounier M, Cohen-Jonathan Moyal E. P01.094 Hypofractionnated Stereotactic Radiation Therapy and Durvalumab combination in recurrent Glioblastoma (GBM): Results of the phase I part of the phase I/II STERIMGLI trial. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - G Peyraga
- Institut Claudius Régaud, Toulouse, France
| | - D Pouessel
- Institut Claudius Régaud, Toulouse, France
| | - A Mervoyer
- Institut René Gauducheau, Nantes, France
| | | | - J Attal
- Institut Claudius Régaud, Toulouse, France
| | - M Robert
- Institut René Gauducheau, Nantes, France
| | | | - M Mounier
- Institut Claudius Régaud, Toulouse, France
| | | |
Collapse
|
11
|
Olivier P, Van Melkebeke D, Honoré PJ, Defreyne L, Hemelsoet D. Cerebral vasospasm in acute porphyria. Eur J Neurol 2017; 24:1183-1187. [DOI: 10.1111/ene.13347] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 05/22/2017] [Indexed: 01/22/2023]
Affiliation(s)
- P. Olivier
- Ghent University Hospital; Ghent Belgium
| | | | | | | | | |
Collapse
|
12
|
Merlin JL, Rauch P, Leufflen L, Salleron J, Harlé A, Olivier P, Marchal F. Abstract P2-01-30: Limited effectiveness of patent blue dye in addition to isotope scanning for identification of sentinel lymph nodes: Cross-sectional real-life study in 1024 breast cancer patients. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-01-30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- J-L Merlin
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| | - P Rauch
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| | - L Leufflen
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| | - J Salleron
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| | - A Harlé
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| | - P Olivier
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| | - F Marchal
- Institut de Cancérologie de Lorraine, Nancy, France; Université de Lorraine, Nancy, France; CNRS UMR7039 CRAN, Vandoeuvre les Nancy, France; CHU, Nancy, France
| |
Collapse
|
13
|
Mukherjee JM, Lindsay C, Mukherjee A, Olivier P, Shao L, King MA, Licho R. Improved frame-based estimation of head motion in PET brain imaging. Med Phys 2017; 43:2443. [PMID: 27147355 DOI: 10.1118/1.4946814] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Head motion during PET brain imaging can cause significant degradation of image quality. Several authors have proposed ways to compensate for PET brain motion to restore image quality and improve quantitation. Head restraints can reduce movement but are unreliable; thus the need for alternative strategies such as data-driven motion estimation or external motion tracking. Herein, the authors present a data-driven motion estimation method using a preprocessing technique that allows the usage of very short duration frames, thus reducing the intraframe motion problem commonly observed in the multiple frame acquisition method. METHODS The list mode data for PET acquisition is uniformly divided into 5-s frames and images are reconstructed without attenuation correction. Interframe motion is estimated using a 3D multiresolution registration algorithm and subsequently compensated for. For this study, the authors used 8 PET brain studies that used F-18 FDG as the tracer and contained minor or no initial motion. After reconstruction and prior to motion estimation, known motion was introduced to each frame to simulate head motion during a PET acquisition. To investigate the trade-off in motion estimation and compensation with respect to frames of different length, the authors summed 5-s frames accordingly to produce 10 and 60 s frames. Summed images generated from the motion-compensated reconstructed frames were then compared to the original PET image reconstruction without motion compensation. RESULTS The authors found that our method is able to compensate for both gradual and step-like motions using frame times as short as 5 s with a spatial accuracy of 0.2 mm on average. Complex volunteer motion involving all six degrees of freedom was estimated with lower accuracy (0.3 mm on average) than the other types investigated. Preprocessing of 5-s images was necessary for successful image registration. Since their method utilizes nonattenuation corrected frames, it is not susceptible to motion introduced between CT and PET acquisitions. CONCLUSIONS The authors have shown that they can estimate motion for frames with time intervals as short as 5 s using nonattenuation corrected reconstructed FDG PET brain images. Intraframe motion in 60-s frames causes degradation of accuracy to about 2 mm based on the motion type.
Collapse
Affiliation(s)
- J M Mukherjee
- Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655
| | - C Lindsay
- Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655
| | | | - P Olivier
- Philips Medical Systems, Cleveland, Ohio 44143
| | - L Shao
- ViewRay, Oakwood Village, Ohio 44146
| | - M A King
- Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655
| | - R Licho
- Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655
| |
Collapse
|
14
|
O'Brien JT, Gallagher P, Stow D, Hammerla N, Ploetz T, Firbank M, Ladha C, Ladha K, Jackson D, McNaney R, Ferrier IN, Olivier P. A study of wrist-worn activity measurement as a potential real-world biomarker for late-life depression. Psychol Med 2017; 47:93-102. [PMID: 27667663 PMCID: PMC5197921 DOI: 10.1017/s0033291716002166] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Revised: 08/01/2016] [Accepted: 08/02/2016] [Indexed: 12/03/2022]
Abstract
BACKGROUND Late-life depression (LLD) is associated with a decline in physical activity. Typically this is assessed by self-report questionnaires and, more recently, with actigraphy. We sought to explore the utility of a bespoke activity monitor to characterize activity profiles in LLD more precisely. METHOD The activity monitor was worn for 7 days by 29 adults with LLD and 30 healthy controls. Subjects underwent neuropsychological assessment and quality of life (QoL) (36-item Short-Form Health Survey) and activities of daily living (ADL) scales (Instrumental Activities of Daily Living Scale) were administered. RESULTS Physical activity was significantly reduced in LLD compared with controls (t = 3.63, p < 0.001), primarily in the morning. LLD subjects showed slower fine motor movements (t = 3.49, p < 0.001). In LLD patients, activity reductions were related to reduced ADL (r = 0.61, p < 0.001), lower QoL (r = 0.65, p < 0.001), associative learning (r = 0.40, p = 0.036), and higher Montgomery-Åsberg Depression Rating Scale score (r = -0.37, p < 0.05). CONCLUSIONS Patients with LLD had a significant reduction in general physical activity compared with healthy controls. Assessment of specific activity parameters further revealed the correlates of impairments associated with LLD. Our study suggests that novel wearable technology has the potential to provide an objective way of monitoring real-world function.
Collapse
Affiliation(s)
- J. T. O'Brien
- Department of Psychiatry, University of Cambridge, Cambridge, UK
| | - P. Gallagher
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
- Newcastle University Institute for Ageing, Newcastle upon Tyne, UK
| | - D. Stow
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - N. Hammerla
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| | - T. Ploetz
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| | - M. Firbank
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - C. Ladha
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| | - K. Ladha
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| | - D. Jackson
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| | - R. McNaney
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| | - I. N. Ferrier
- Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK
| | - P. Olivier
- Open Lab, Newcastle University, Newcastle upon Tyne, UK
| |
Collapse
|
15
|
Manousaki D, Deladoëy J, Geoffroy L, Olivier P. Continuous Subcutaneous Insulin Infusion in Children: A Pilot Study Validating a Protocol to Avoid Hypoglycemia at Initiation. Front Endocrinol (Lausanne) 2017; 8:84. [PMID: 28484424 PMCID: PMC5401867 DOI: 10.3389/fendo.2017.00084] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Accepted: 03/31/2017] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND The occurrence of hypoglycemia and hyperglycemia during the first days after transition to continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes has not been systematically studied in children. The aim of this prospective study was to demonstrate that the protocol applied in our diabetes clinic is safe at CSII initiation in children. METHODS We assessed 22 pediatric patients with type 1 diabetes, using continuous glucose monitoring (CGM) before and after CSII initiation (±3 days). RESULTS After CSII initiation, there was no difference in the rates of hypoglycemic events expressed as relative rates (RRs) per person-reading (RR = 0.85, p = 0.52, 95% CI 0.52-1.39), as well as in the number of prolonged hypoglycemic events (>1 h) per day (RR = 1.12, p = 0.56, 95% CI 0.75-1.68). We observed only a trend toward prolonged episodes of hyperglycemia after pump initiation (RR = 1.52, p = 0.06, 95% CI 0.97-2.35). CONCLUSION Our study is the first to assess, through CGM and in a prospective way, the impact of a CSII initiation protocol on glycemic values. Our protocol provides a safe model to avoid hypoglycemia at CSII initiation in children. CLINICAL TRIAL REGISTRATION www.ClinicalTrials.gov, identifier NCT01840358.
Collapse
Affiliation(s)
- Despoina Manousaki
- Endocrinology Service and Diabetes Unit, CHU Sainte-Justine, Montreal, QC, Canada
- Department of Pediatrics, University of Montreal, Montreal, QC, Canada
| | - Johnny Deladoëy
- Endocrinology Service and Diabetes Unit, CHU Sainte-Justine, Montreal, QC, Canada
- Department of Pediatrics, University of Montreal, Montreal, QC, Canada
| | - Louis Geoffroy
- Endocrinology Service and Diabetes Unit, CHU Sainte-Justine, Montreal, QC, Canada
- Department of Pediatrics, University of Montreal, Montreal, QC, Canada
| | - Patricia Olivier
- Endocrinology Service and Diabetes Unit, CHU Sainte-Justine, Montreal, QC, Canada
- Department of Pediatrics, University of Montreal, Montreal, QC, Canada
- *Correspondence: Patricia Olivier,
| |
Collapse
|
16
|
Blum A, Gondim-Teixeira P, Gabiache E, Roche O, Sirveaux F, Olivier P, Coudane H, Raymond A, Louis M, Grandhaye M, Meyer JB, Mainard D, Molé D. Developments in imaging methods used in hip arthroplasty: A diagnostic algorithm. Diagn Interv Imaging 2016; 97:735-47. [PMID: 27452630 DOI: 10.1016/j.diii.2016.07.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Accepted: 07/01/2016] [Indexed: 01/26/2023]
Abstract
BACKGROUND Several imaging modalities can be used to diagnose complications of hip prosthesis placement. Despite progress in these imaging techniques, there are, as yet, no guidelines as to their respective indications. METHODS We formed a panel of experts in fields related to prosthesis imaging (radiology, nuclear medicine, orthopedic surgery) and conducted a review of the literature to determine the value of each modality for diagnosing complications following hip replacement. RESULTS Few recent studies have investigated the benefits related to the use of the latest technical developments, and studies comparing different methods are extremely rare. CONCLUSIONS We have developed a diagnostic tree based on the characteristics of each imaging technique and recommend its use. Computed topography was found to be the most versatile and cost-effective imaging solution and therefore a key tool for diagnosing the complications of hip replacement surgery.
Collapse
Affiliation(s)
- A Blum
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - P Gondim-Teixeira
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - E Gabiache
- Service de médecine nucléaire, CHU de Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy cedex, France.
| | - O Roche
- Centre chirurgical Émile-Gallé, 49, rue Hermite, 54000 Nancy, France.
| | - F Sirveaux
- Centre chirurgical Émile-Gallé, 49, rue Hermite, 54000 Nancy, France.
| | - P Olivier
- Service de médecine nucléaire, CHU de Nancy, rue du Morvan, 54511 Vandœuvre-lès-Nancy cedex, France.
| | - H Coudane
- Chirurgie traumatologique et arthroscopique de l'appareil locomoteur (ATOL), CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | | | - A Raymond
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - M Louis
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - M Grandhaye
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - J-B Meyer
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - D Mainard
- Chirurgie orthopédique et traumatologique (COT), CHU de Nancy, avenue de Maréchal-de-Lattre-de-Tassigny, 54035 Nancy, France.
| | - D Molé
- Centre chirurgical Émile-Gallé, 49, rue Hermite, 54000 Nancy, France.
| |
Collapse
|
17
|
Aptel S, Lecocq-Teixeira S, Olivier P, Regent D, Gondim Teixeira P, Blum A. Multimodality evaluation of musculoskeletal sarcoidosis: Imaging findings and literature review. Diagn Interv Imaging 2016; 97:5-18. [DOI: 10.1016/j.diii.2014.11.038] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2014] [Revised: 10/23/2014] [Accepted: 11/06/2014] [Indexed: 10/23/2022]
|
18
|
|
19
|
François C, Olivier P, Rouillier M, Leduc-Gaudet J, Bradette F, St-Pierre D. Etiology of Excessive Lipid Accumulation in Pre-Myocyte Cells. Can J Diabetes 2015. [DOI: 10.1016/j.jcjd.2015.01.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Faivre J, Charra-Brunaud C, Peiffert D, Olivier P, Guillemin F, Desandes E. Impact des facteurs cliniques et dosimétriques sur le contrôle local de la curiethérapie utérovaginale intracavitaire de bas débit de dose pulsé dans les cancers du col de l’utérus : résultat d’une cohorte de l’institut de cancérologie de Lorraine. Cancer Radiother 2014. [DOI: 10.1016/j.canrad.2014.07.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
21
|
Rashotte J, Tousignant K, Richardson C, Fothergill-Bourbonnais F, Nakhla MM, Olivier P, Lawson ML. Living with Sensor-Augmented Pump Therapy in Type 1 Diabetes: Adolescents' and Parents' Search for Harmony. Can J Diabetes 2014; 38:256-62. [DOI: 10.1016/j.jcjd.2014.02.002] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 02/03/2014] [Accepted: 02/03/2014] [Indexed: 10/25/2022]
|
22
|
Olivier P, Lawson ML, Huot C, Richardson C, Nakhla M, Romain J. Lessons learned from a pilot RCT of simultaneous versus delayed initiation of continuous glucose monitoring in children and adolescents with type 1 diabetes starting insulin pump therapy. J Diabetes Sci Technol 2014; 8:523-8. [PMID: 24876616 PMCID: PMC4455437 DOI: 10.1177/1932296814524855] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Uncertainty remains about effectiveness of continuous glucose monitoring (CGM) in pediatric type 1 diabetes (T1D). Success with CGM is related to CGM adherence, which may relate to readiness to make the behavior changes required for effective use. We hypothesize that readiness for change will be greater at initiation of insulin pump therapy than in established pump users, and that this will predict CGM adherence. Our objective was to evaluate the feasibility of a randomized controlled trial (RCT) in children with established T1D comparing simultaneous pump and CGM initiation to standard pump therapy with delayed CGM initiation. We randomized participants to simultaneous pump and CGM initiation or to standard pump therapy with the option of adding CGM 4 months later. CGM adherence was tracked via web-based download and readiness for change assessed with the SOCRATES questionnaire. Of 41 eligible children, 20 agreed to participate; 15 subjects completed the study (7 males; baseline age 11.8 ± 4.0 years; T1D duration 2.7 ± 2.7 years; mean A1C 8.2 ± 0.8%). Six of 8 simultaneous group subjects used CGM > 60% of the time for 4 months compared to 1 of 7 delayed group subjects (P = .02). Using SOCRATES, we could assign 87-100% of subjects to a single motivation stage at baseline and 4 months. This pilot study demonstrates the feasibility of randomizing pump naïve children and adolescents with established T1D to simultaneous pump and CGM initiation versus standard pump therapy with delayed CGM initiation. Lessons from this pilot study were used to inform development of a full-scale multicenter RCT.
Collapse
Affiliation(s)
- Patricia Olivier
- Endocrinology Service, Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada
| | - Margaret L Lawson
- Division of Endocrinology & Metabolism, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada
| | - Celine Huot
- Endocrinology Service, Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada
| | - Christine Richardson
- Division of Endocrinology & Metabolism, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada
| | - Meranda Nakhla
- Division of Endocrinology & Metabolism, Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada
| | - Judette Romain
- Endocrinology Service, Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Quebec, Canada
| |
Collapse
|
23
|
Couturier O, Rousseau C, Pierga JY, Berriolo-Riedinger A, Alberini JL, Girault S, Fumoleau P, Brain E, Abadie-Lacourtoisie S, Vera P, Liehn JC, Olivier P, Uwer L, Cachin F, Sagan C, Bouchet F, Lebas N, Mesleard C, Fourme E, Martin AL, Lovinfosse P, Lacœuille F, Campone M. Abstract P4-01-05: 3’-deoxy-3’-[18F]fluoro-thymidine (18F-FLT) positron emission tomography (PET): An accurate and effective tool for assessing tumor response in breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-01-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives : A French multicenter study was promoted by the national French cancer federation (Unicancer R&D) to assess the potential of [18F]FLT (positron emission tomography (PET) biomarker of proliferation)to manage breast cancer neoadjuvant chemotherapy (NAC). The main objective was to compare changes in tumor [18F]FLT uptake to histopathological changes induced by NAC, assuming an arrest of tumor growth related to the effectiveness of NAC.
Methods : 97 patients (age 48.6 +/- 10.2 y.) were included in 13 nuclear medicine centers. All patients were eligible to anthracycline-based NAC for a de novo unifocal breast cancer (ductal n = 84, lobular = 11, other type = 2; stage II n = 75, stage III n = 21 et stage IV n = 1). 90 patients underwent a baseline PET before the onset of NAC (PET1) and a final PET after the end of NAC and before surgery (PET3). PET acquisitions were performed 60±7min after FLT injection. SUVmax (maximum standardized uptake value), SUVpeak (1 cm3 ROI including pixel max) and SUV41 (isocontour 41% of pixel max) were computed. Changes in SUV on PET3 vs PET1 were analyzed in relation to histopathological findings at the end of NAC (Sataloff criteria).
Results : Tumor FLT uptake decreased markedly between TEP1 and TEP3 (SUVmax = 6.2±4.8 vs 1.3±1.2 respectively; SUVpeak = 4.6±3.2 vs 0.9±0.9; SUV41 = 3.6±2.8 vs 0.8±0.7). Total or near-total therapeutic effect (grade A) were obtained in 20 patients, more than 50% therapeutic effect but less than total or near-total effect (grade B) in 37 patients, less than 50% therapeutic effect but visible effect (grade C) in 22 patients, or no therapeutic effect (grade D) in 11 patients. SUVmax decreased dramatically (87.5%) to background levels in all patients with a complete response (grade A). Overall, changes in SUV differed depending on the type of histological response (p<0.01) i.e. SUVmax changes were more pronounced as pathological responses were good: 61% for grade D; 65.7% grade C and 69.8% grade B. The same results were obtained with the two other SUV types.
Conclusions : Pathologic response to NAC in breast cancer can be assessed accurately by FLT.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-01-05.
Collapse
Affiliation(s)
- O Couturier
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - C Rousseau
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - J-Y Pierga
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - A Berriolo-Riedinger
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - J-L Alberini
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - S Girault
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Fumoleau
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - E Brain
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - S Abadie-Lacourtoisie
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Vera
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - J-C Liehn
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Olivier
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - L Uwer
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - F Cachin
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - C Sagan
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - F Bouchet
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - N Lebas
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - C Mesleard
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - E Fourme
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - A-L Martin
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - P Lovinfosse
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - F Lacœuille
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| | - M Campone
- Centre Hospitalier Universitaire, Angers, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Insitut Curie, Saint Cloud, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Centre Hospitalier Universitaire, Nancy, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire, Saint Herblain, France; R&D Unicancer, Paris, France
| |
Collapse
|
24
|
Dubray B, Mezzani-Saillard S, Édet-Sanson A, Ménard JF, Modzelewski R, Thureau S, Meyer ME, Jalali K, Bardet S, M’Vondo CM, Houzard C, Mornex F, Olivier P, Faure G, Rousseau C, Mahé MA, Gomez P, Brenot-Rossi I, Salem N, Vera P. La SUVmax (standard uptake value maximale) mesurée en cours de radiothérapie pour cancer bronchique non à petites cellules est prédictive de la survie sans récidive à un an : étude prospective et multicentrique. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
25
|
Louvel G, Olivier P, Gillet N, Rodrigues C, De Crevoisier R. 18F-FDG PET As A Predictor Of Survival In Radiotherapy For Head and Neck Cancer Patients. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Leseur J, Louvel G, Devillers A, Olivier P, Gillet N, Rodrigues C, Williaume D, Arango JO, Garin E, De Crevoisier R. 2000 ORAL Prognostic Value of Metabolic Response Assessed by 18F-FDG PET During Radiotherapy for Cervix and Head and Neck Carcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70958-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
27
|
Oldrini G, Geoffrois L, Olivier P, Henrot P, Blum A. [Metastatic paraganglioma. Answer to May e-quid]. ACTA ACUST UNITED AC 2011; 92:739-43. [PMID: 21819919 DOI: 10.1016/j.jradio.2011.03.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2011] [Accepted: 03/18/2011] [Indexed: 11/28/2022]
Affiliation(s)
- G Oldrini
- Service d'imagerie Guilloz, CHU de Nancy, avenue de Lattre-de-Tassigny, 54000 Nancy, France
| | | | | | | | | |
Collapse
|
28
|
Zender HO, Olivier P, Genné D. [Acute community-acquired bacterial meningitis in adults]. Rev Med Suisse 2009; 5:1968-1974. [PMID: 19908635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Bacterial meningitis in adults is fatal in 20% of patients and leads to sequels in 30%. The clinical presentation includes two of the following four symptoms and signs: fever, headache, stiff neck, altered mental status. The essential ancillary test is the analysis of the cerebrospinal fluid. Sometimes, the lumbar puncture is not feasible or deferred (brain computer tomography), requiring antibiotics and corticosteroids early. 80% of bacterial meningitis are secondary to pneumococcus or meningococcus. Empirical antibiotics must be given as soon as possible and provide coverage for these both bacteria. Corticosteroids are also recommended for some meningitis. A score can predict the evolution. Preventive measure must be taken for close contacts of a patient with a meningococcal meningitis.
Collapse
Affiliation(s)
- H O Zender
- Service des soins intensifs, Département de médecine cantonal, Hôpital neuchâtelois-La Chaux-de-Fonds, Rue de Chasseral 20, 2300 La Chaux-de-Fonds.
| | | | | |
Collapse
|
29
|
Sénéclauze-Seguin V, Olivier P, Jeanine O, Christiane W, Israël N. The impact of obesity on implantation rates and the outcomes of first trimester pregnancies after assisted reproductive treatment. Fertil Steril 2009. [DOI: 10.1016/j.fertnstert.2009.07.1069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
30
|
Baud O, Olivier P, Vottier G, Pham H, Mercier JC, Loron G. Effet du NO inhalé sur le poumon et le cerveau en développement. Arch Pediatr 2009; 16 Suppl 1:S1-8. [DOI: 10.1016/s0929-693x(09)75295-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Meneroux B, Mandry D, Djaballah W, Koehl G, Grandpierre S, Netter F, Didot N, Gillet N, Veyre L, Rossignol P, Regent D, Olivier P, Karcher G, Marie PY. A020 Analyse quantitative de la captation du 18F-fluorodéoxyglucose dans les parois d’anévrysmes de l’aorte abdominale traités médicalement. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72153-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Maalouf T, George JL, Geoffrois L, Olivier P, Dolivet G. [Sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumors: report of 8 cases]. Rev Laryngol Otol Rhinol (Bord) 2009; 130:231-234. [PMID: 20597403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
OBJECTIVE To report our experience in sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumours. METHODS AND RESULTS Preliminary study (2005-2007) on 8 patients with conjunctival and or eyelid tumours (melanomas, epidermoid carcinoma, Merkel cell carcinoma). All patients underwent preoperative lymphoscintigraphy 18 FdG pet CT Surgery was performed with complete neck dissection. Sentinel nodes and other nodes harvested were processed separately for histopathologic study; the sentinel were confirmed as histologicaly positive for five patients. Additional positive nodes were found in two out of those five patients. No positive lymph node was found in patients with negative lymphoscintigraphy. After a follow up ranging from 12 to 43 months: two patients died, and 6 are free of disease. CONCLUSIONS These results demonstrate a very hight level of invaded NO lymph node and confirm the interest of sentinel node technique for optimisation of the therapeutic strategy in lymphophilic conjunctival and eyelid tumours.
Collapse
Affiliation(s)
- T Maalouf
- CHU Nancy-Brabois, Service d'ophtalmologie B, Rue du Morvan, 54511 Vandoeuvre les Nancy, France.
| | | | | | | | | |
Collapse
|
33
|
Leclaire C, Saadi L, Scigliano S, Olivier P, Wahl D. Impact de la Tomoscintigraphie par Emission de Positons dans la prise en charge des vascularites. Rev Med Interne 2008. [DOI: 10.1016/j.revmed.2008.03.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
34
|
Abstract
The presence of distant metastases from differentiated thyroid carcinoma decreases the 10-year survival of patients by 50%. Bone metastases represent a frequent complication especially of follicular thyroid cancer and severely reduce the quality of life causing pain, fractures, and spinal cord compression. Diagnosis is established by correlating clinical suspicion with imaging. Imaging is essential to detect, localize, and assess the extension of the lesions and should be used in conjunction with clinical evidence. Bone metastases are typically associated with elevated markers of bone turnover, but these markers have not been evaluated in differentiated thyroid cancer. Skeletal and whole-body magnetic resonance imaging and fusion 2-deoxy-2-[18F]fluoro-D-glucose whole-body positron emission tomography/computed tomography (PET/CT) are the best anatomic and functional imaging techniques available in specialized centers. For well-differentiated lesions, iodine-PET scan combined (124)I-PET/CT is the newest imaging development and (131)I is the first line of treatment. Bisphosphonates reduce the complications rate and pain, alone or in combination with radioiodine, radionuclides, or external beam radiotherapy and should be employed. Surgery and novel minimally invasive consolidation techniques demand an appropriate patient selection for best results on a multimodal approach. Basic research on interactions between tumor cells and bone microenvironment are identifying potential novel targets for future more effective therapeutic interventions for less differentiated tumors.
Collapse
Affiliation(s)
- M M Muresan
- Endocrinology Department and Nuclear Medicine Department, Hôpital Brabois Adultes, CHU Nancy, Vandoeuvre, France.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Souyri C, Olivier P, Grolleau S, Lapeyre-Mestre M. Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol 2008; 33:249-55. [PMID: 18261144 DOI: 10.1111/j.1365-2230.2007.02652.x] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND Severe necrotizing soft-tissue infection (NSTI) is a rare but potentially life-threatening condition if not recognized and treated early. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been implicated as a contributing factor, but their role remains debated. AIMS The aim of our study was to investigate the potential relationship between cases of NSTI recorded in the French Pharmacovigilance system and exposure to NSAIDs. METHODS Cases of NSTI and randomly selected matched noncase controls (without skin disease) were identified in the database of the Spontaneous Reporting System in France for the period 2000-2004. Exposure to NSAIDs and other factors were investigated using conditional logistic regression. RESULTS We found 38 cases of NSTI in 2000-04: 12 infants (0-23 months), 16 children (2-15 years) and 10 adults (>15 years), and we selected 228 controls. The median age of the sample was 4 years. Of the 38 cases, 25 were exposed to ibuprofen and 24 presented with varicella. The adjusted odds ratio for exposure to NSAIDs was 31.38 (95% CI 6.40-153.84), and 17.55 (95% CI 3.47-88.65) for viral infection. Other predisposing factors (diabetes, immunosuppression, injecting drugs) were not found to be associated, although this may have been due to the very small number of cases of NSTI/necrotizing fasciitis in adults reported in the database. CONCLUSION Despite the limitations related to a spontaneous reporting system, this study indicates a strong association between NSAID use and NSTI. Although it was not possible to conclude if NSAIDs increase the risk of necrotizing complications in all patients, their use may mask the symptoms and delay diagnosis.
Collapse
Affiliation(s)
- C Souyri
- Department of Clinical Pharmacology, Pharmacovigilance Regional Centre, Toulouse University Hospital, Toulouse, France
| | | | | | | | | |
Collapse
|
37
|
Abstract
Nefopam is widely used for the relief of moderate acute pain. Its safety profile remains to be specified. The objective of the study was to review adverse reactions to nefopam spontaneously reported to the French Pharmacovigilance system. All cases of adverse drug reactions (ADRs) associated with nefopam, registered in the French Pharmacovigilance database from January 1, 1995 to December 31, 2004, were reviewed. For each reported ADR, information about patient (age, gender, medical history), drug exposure (suspected and concomitantly used drugs), characteristics of ADRs (imputability score, time of onset, seriousness, outcome) were collected. A total of 114 ADRs with an imputability rated from 'plausible' (I2) to 'likely' (I3) and 'very likely' (I4) was analysed. The most frequent ADRs included 'expected' ADRs such as sweating, nausea, tachycardia, malaise or vomiting; 61 ADRs were 'unexpected. No overdose was reported; 26 ADRs (23%) were considered as 'serious'. Most of them were 'unexpected', including neuropsychiatric (hallucinations, convulsions) or cutaneous (pruritus, erythema, urticaria) ADRs. Six cases of anaphylactic ADRs (two angioedema and four anaphylactic shocks) were reported, all occurring shortly after use of nefopam during the post-operative period. Physicians should be aware of the possible occurrence of some serious ADRs when using nefopam such as convulsions and anaphylactic shocks, especially when the drug is used in special medical conditions, like post-operative periods.
Collapse
Affiliation(s)
- G Durrieu
- Service de Pharmacologie Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
| | | | | | | |
Collapse
|
38
|
Montjaux-Régis N, Chanot A, Olivier P, Damase-Michel C, Mengelle C, Glorieux I, Casper C. Entérocolite ulcéronécrosante chez un nouveau-né à terme. Rôle de l'acyclovir? Arch Pediatr 2007; 14:1420-3. [DOI: 10.1016/j.arcped.2007.08.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2006] [Accepted: 08/29/2007] [Indexed: 11/29/2022]
|
39
|
Baud O, Fontaine R, Olivier P, Maury L, El Moussawi F, Bauvin I, Arsac M, Hovhannisyan S, Farnoux C, Aujard Y. Rupture très prématurée des membranes: physiopathologie des conséquences neurologiques. Arch Pediatr 2007; 14 Suppl 1:S49-53. [DOI: 10.1016/s0929-693x(07)80011-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Abstract
The authors report a patient with unilateral painful hand and moving finger in whom tactile stimulation interrupted both the movement and the pain. This effect suggests a gating mechanism at a segmental level. The difference between afferent and efferent pathway levels and the delay of several months between trauma and occurrence of symptoms support a central mechanism, most probably involving sensorimotor reorganization at a segmental level.
Collapse
Affiliation(s)
- C Wider
- Department of Neurology, University Hospital, Lausanne, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Adle-Biassette H, Baud O, Verney C, Olivier P, Gressens P, Mikol J, Massias L, Evrard P, Hénin D. Lésions corticales induites par l’inhibition du transport de monocarboxylate durant le développement cérébral chez la souris. Rev Neurol (Paris) 2005. [DOI: 10.1016/s0035-3787(05)85202-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
42
|
Durrieu G, Olivier P, Montastruc JL. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database. Eur J Clin Pharmacol 2005; 61:611-4. [PMID: 16133552 DOI: 10.1007/s00228-005-0964-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2005] [Accepted: 06/02/2005] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To evaluate the main characteristics of case reports of arterial hypertension (AH) related to COX-2 inhibitor (coxib) use in real-life practice. METHODS This study was based on spontaneous reports of adverse drug reactions (ADRs) submitted to the French Pharmacovigilance system. Associations between AH and the different groups of those using non-steroidal anti-inflammatory drugs (NSAIDs: rofecoxib, celecoxib and non-selective NSAIDs) were compared using calculation of the odds ratio (OR) with 95% confidence intervals (CIs). RESULTS In France, between 1 April 2000 and 30 November 2003, 34 AH cases related to coxibs were reported. Case reports include predominantly patients older than 65 years, with a previous story of essential AH. Most AH (60%) occurred during the first 15 days of treatment. The AH was reported significantly more frequently for rofecoxib than celecoxib. The OR for development of AH with rofecoxib versus celecoxib was 3.3 (1.6-6.9). The AH was also reported more frequently with coxib (2.8%) than with non-selective NSAID (0.5%) use, OR = 5.9 (3.8-9.0). CONCLUSION This study shows that coxibs are associated with a risk of AH in real-life practice. More spontaneous reports of AH to the French Pharmacovigilance system concern rofecoxib than celecoxib (and coxibs than non-selective NSAIDs). This ADR is of special epidemiological importance due to both the risks of AH and the large use of coxibs.
Collapse
Affiliation(s)
- G Durrieu
- Faculté de Médecine de Toulouse, Unité de Pharmacoépidémiologie UA 3696, IFR INSERM 126, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmaco épidémiologie et d'Informations sur le Médicament, Toulouse, France.
| | | | | |
Collapse
|
43
|
Du Toit DE, Olivier P, Grenfell L, Eksteen B. Isokinetic neck strength norms for schoolboy rugby forwards. S Afr J SM 2005. [DOI: 10.17159/2413-3108/2005/v17i1a175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Objective. To generate isokinetic neck strength norms for schoolboy rugby forwards. Design. Two hundred and eight schoolboys (17.21 – 1.03 years, mean – standard error of the mean (SEM), chosen from a population of under-19 first and second XV rugby players, participated in this study. The subjects were assessed anthropometrically and isokinetically according to a set protocol. The isokinetic assessment of neck strength was performed with the use of a specially designed stabilising chair and halo. The subjects performed a single maximal exertion set, consisting of 3 repetitions, through each of the cervical spinal movements in the sagittal and frontal planes. The data were analysed statistically according to positional categories (front-, second-, and back-row forwards), and were used to generate Stanine tables of normative data concerning the force characteristics of the cervical spine. Results. The front-row forwards produced the largest amounts of force during the measurement of peak torque flexion (PTF = 30.00 – 1.39 Nm) and peak torque extension (PTE = 55.26 – 1.42 Nm). Conversely, the second-row forwards performed the best during the measurement of lateral flexion peak torque to the right (PTR = 53.71 – 1.51 Nm) and lateral flexion peak torque to the left (PTL = 52.92 – 1.63 Nm) in the frontal plane. The front-row forwards were the most powerful in all the neck movements measured (power generated at 0.2 seconds during flexion (PowF) = 101.54 – 6.43 W, power generated at 0.2 s during extension (PowE) = 167.31 – 8.03 W, power generated at 0.2 s during lateral flexion to the right (PowR) = 211.92 – 7.44 W, and power generated at 0.2 s during lateral flexion to the left (PowL) = 194.81 – 7.73 W). However, further analysis of the data revealed that few statistically significant differences (p < 0.01 and p < 0.05) existed between the positional categories for the measured variables of peak torque, power generated at 0.2 of a second, peak torque to body mass ratio and cervical range of motion. Conclusion. It appears that the various positional categories have not undergone the expected neck strength adaptations to meet the unique requirements of each position. The generation of neck strength normative data allows for the effective and quantified comparison of neck strength variables, enabling more effective injury prevention and rehabilitation. South African Sports Medicine Vol.17(1) 2005: 19-26
Collapse
|
44
|
Abstract
Objective. To generate isokinetic neck strength norms for schoolboy rugby forwards.
Design. Two hundred and eight schoolboys (17.21 – 1.03 years, mean – standard error of the mean (SEM), chosen from a population of under-19 first and second XV rugby players, participated in this study. The subjects were assessed anthropometrically and isokinetically according to a set protocol. The isokinetic assessment of neck strength was performed with the use of a specially designed stabilising chair and halo. The subjects performed a single maximal exertion set, consisting of 3 repetitions, through each of the cervical spinal movements in the sagittal and frontal planes. The data were analysed statistically according to positional categories (front-, second-, and back-row forwards), and were used to generate Stanine tables of normative data concerning the force characteristics of the cervical spine.
Results. The front-row forwards produced the largest amounts of force during the measurement of peak torque flexion (PTF = 30.00 – 1.39 Nm) and peak torque extension (PTE = 55.26 – 1.42 Nm). Conversely, the second-row forwards performed the best during the measurement of lateral flexion peak torque to the right (PTR = 53.71 – 1.51 Nm) and lateral flexion peak torque to the left (PTL = 52.92 – 1.63 Nm) in the frontal plane. The front-row forwards were the most powerful in all the neck movements measured (power generated at 0.2 seconds during flexion (PowF) = 101.54 – 6.43 W, power generated at 0.2 s during extension (PowE) = 167.31 – 8.03 W, power generated at 0.2 s during lateral flexion to the right (PowR) = 211.92 – 7.44 W, and power generated at 0.2 s during lateral flexion to the left (PowL) = 194.81 – 7.73 W). However, further analysis of the data revealed that few statistically significant differences (p < 0.01 and p < 0.05) existed between the positional categories for the measured variables of peak torque, power generated at 0.2 of a second, peak torque to body mass ratio and cervical range of motion.
Conclusion. It appears that the various positional categories have not undergone the expected neck strength adaptations to meet the unique requirements of each position. The generation of neck strength normative data allows for the effective and quantified comparison of neck strength variables, enabling more effective injury prevention and rehabilitation.
South African Sports Medicine Vol.17(1) 2005: 19-26
Collapse
|
45
|
Ssi yan kai I, Olivier P, Verney C, Plaisant F, Gressens P, Bremond-Gignac D. 385 Étude des effets des corticoïdes sur le développement du nerf optique du rat. J Fr Ophtalmol 2005. [DOI: 10.1016/s0181-5512(05)73506-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
46
|
Adle-Biassette H, Henin D, Verney C, Olivier P, Gressens P, Evrard P, Baud O. Lésions corticales induites par l’inhibition de transport de monocarboxylates durant le développement cérébral chez la souris. Ann Pathol 2004. [DOI: 10.1016/s0242-6498(04)94163-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
de la Blanchardière A, Méouchy G, Brunel P, Olivier P. Étude prospective des caractéristiques médicopsychosociales de 350 patients ayant consulté une permanence d’accès aux soins de santé en 2002. Rev Med Interne 2004; 25:264-70. [PMID: 15050793 DOI: 10.1016/j.revmed.2003.09.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2003] [Accepted: 09/01/2003] [Indexed: 11/28/2022]
Abstract
PURPOSE Precariousness and its consequences have not been re-evaluated in France since the introduction of the Law to fight exclusion, which instituted Universal Medical Cover (CMU) and permanently maintained health care facilities (PASS) in 1998. METHOD Throughout the year 2002, a descriptive medical, psychological and social prospective study was carried out amongst PASS patients seen in 2002 at Avignon Hospital. RESULTS Three hundred and fifty out of 359 patients have been analysed. Most of them were adults (93%), young (mean age 38), male (56%), foreigners from non-EU countries (73%), with an illegal status (69%). They were without any declared income (77%), but with accommodation (67%), living as married (or such) or single in equal proportion. They were often without social security cover (48%). Their dominant pathologies were infections (42% of the patients). The most frequently diagnosed conditions were obesity (14%), pregnancy (8%), lower back pain (7%), high blood pressure (7%), chronic hepatitis C virus infection (6%), fungal infections (6%) and traumas (6%). Dental (43%) and psychiatric (27%) disorders were very frequent. The analysis of sub-groups has shown that some disorders are more frequent in French and European patients: chronic hepatitis C virus infection (14% vs. 4%), traumas (14% vs. 4%), psychopathy (11% vs. 0%), alcohol abuse (32% vs. 5%), smoking (80% vs. 25%), cannabis (20% vs. 2%) or opioids (16% vs. 0%) use. CONCLUSION Access to health care has been difficult in 2002 in Avignon mostly for illegal immigrants for whom the only valid response should be of a political nature. Both French and European communities who still do not benefit from CMU improvements probably mean local interventions and combined operations because of the homelessness and the addictions of these people.
Collapse
Affiliation(s)
- A de la Blanchardière
- Permanence d'accès aux soins de santé, pôle santé publique, hôpital H.-Duffaut, 305, rue R.-Follereau, 84902 Avignon cedex, France.
| | | | | | | |
Collapse
|
48
|
Watrin-Pinzano A, Ruaud JP, Cheli Y, Gonord P, Grossin L, Gillet P, Blum A, Payan E, Olivier P, Guillot G, Netter P, Loeuille D. T2 mapping: an efficient MR quantitative technique to evaluate spontaneous cartilage repair in rat patella. Osteoarthritis Cartilage 2004; 12:191-200. [PMID: 14972336 DOI: 10.1016/j.joca.2003.10.010] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/21/2003] [Accepted: 10/20/2003] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To evaluate the ability of T2 mapping on an 8.5 T imager to characterize morphologically and quantitatively spontaneous repair of rat patellar cartilage following full thickness defect. METHODS Patellar cartilage defects were created in 24 rats knees on D0. Eight rats per time-point were killed on D20, D40 and D60 after surgery. T2 maps of repair tissue in patellar defects were obtained from eight different axial spin echo images on an 8.5 T imager. Global, superficial and deep T2 values were evaluated in spontaneous repair tissues (3x8 right patellae) vs the opposite patellae (3x8 left patellae) of the same animals. MR data were compared with macroscopic and histological studies. RESULTS T2 map was able to identify morphologically three types of repair tissue observed macroscopically and histologically: 'total', 'partial' and 'hypertrophic' repair tissue. 'Total' and 'partial' repair tissues were characterized by global T2 values almost similar to controls, whereas 'hypertrophic' repair tissues were characterized by T2 global values higher than controls. Zonal variation between superficial and deep T2 values observed in controls was not depicted in repair tissue before D60. CONCLUSION T2 map is able to characterize quantitatively and qualitatively rat patellar cartilage repair, and thus can be promoted, as a non invasive technique, in clinical longitudinal studies of articular cartilage repair.
Collapse
Affiliation(s)
- A Watrin-Pinzano
- Department of Pharmacology, UMR 7561 CNRS-Nancy I, Physiopathologie et Pharmacologie Articulaires, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Hubert J, Descotes JL, Olivier P. [Urology imaging: positron emission imaging]. Prog Urol 2003; 13:807-12. [PMID: 14763383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
|
50
|
de La Blanchardière A, Guillaume J, Slama B, Oliveri D, Olivier P, Arlaud J. Névrite optique rétrobulbaire récidivant sous azathioprine au cours d'une maladie de Behçet. Rev Med Interne 2003. [DOI: 10.1016/s0248-8663(03)80252-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|